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Development of oral 5-fluorouracil (5-FU) antitumour drugs
started in Japan in 1971, focusing on the fact that 5-FU acts in a
time-dependent manner (Unemi et al, 1971), and, such drugs as
uracil-tegafur (UFT) are currently being widely used in Japan to
treat various types of cancer, including NSCLC, in combination
with other drugs, such as cisplatin. Oral drugs enable patients to
undergo treatment as outpatients, and they are suitable for main-
taining patients’ quality of life. 
S-1 is a novel oral fluorpyrimidine derivative consisting of
tegafur (FT) and 2 modulators, 5-chloro-2, 4-dihydroxypyridine
(CDHP) and potassium oxonate (Oxo), in a molar ratio of 1:0.4:1
(Shirasaka et al, 1996) FT is a prodrug of 5-FU (Giller et al, 1967).
CDHP is a reversible competitive inhibitor of dihydropyrimidine
dehydrogenase (DPDase; EC1.3.1.2), an enzyme involved in the
degradation of 5-FU (Tatsumi et al, 1987). Thus, the degradation
of FT-derived 5-FU is efficiently inhibited by CDHP, and 5-FU
remains in plasma and tumour tissue longer and at higher levels
than when low-dose 5-FU is continuously infused intravenously.
This has resulted in enhancement of the antitumour effect in an
animal model (Shirasaka et al, 1996). The major toxicities of fluo-
ropyrimidines are diarrhoea and mucositis (Vogelzang, 1984). Oxo
is a reversible competitive inhibitor of orotate phosphoribosyl-
transferase (EC2.4.2.10), a phosphoenzyme for 5-FU, and is
distributed at high levels in the gastrointestinal (GI) tract after oral
administration, resulting in a reduction in GI toxicity caused by 
5-FU (Shirasaka et al, 1993). 
Based on the results of a phase I clinical trial, the maximum
tolerated dose was concluded to be 75–100 mg body–1, twice daily
(as FT), and the dose-limiting factor was myelosuppression, espe-
cially leukopenia (Taguchi et al, 1994). In an early phase II clinical
trial, the initial dosing schedule was 75 mg body–1 b.i.d for 28
consecutive days followed by a 2-week rest period. However, the
dose was reduced to 50 mg body–1 b.i.d. because of skin rashes,
severe myelosuppression, and diarrhoea. The response rate was
12.5% (5/40) in chemotherapy-naive patients. The major grade 3
or more toxicities were myelosuppression and gastrointestinal
toxicity (Hino et al, 1996). When the actual administered doses
were calculated according to body surface area (BSA), the rate of
discontinuation of the drug because of toxicities was 71.4% (5/7)
at 90 mg m–2 day–1. We therefore set the initial dose at 80 mg m–2
day-1 for this late phase II study. 
To confirm the antitumour effect and safety of this drug, a multi-
centre late phase II clinical trial was conducted in 27 facilities in
Japan. 
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Summary The purpose of this study was to evaluate the efficacy and safety of a novel oral anticancer fluoropyrimidine derivative, S-1, in
patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer (NSCLC). Between June 1996 and July 1998,
62 patients with NSCLC who had not received previous chemotherapy for advanced disease were enrolled in this study. 59 patients (22 stage
IIIB and 37 stage IV) were eligible for the evaluation of efficacy and safety. S-1 was administered orally, twice daily, after meals. 3 dosages of
S-1 were prescribed according to body surface area (BSA) so that they would be approximately equivalent to 80 mg m–2 day–1: BSA < 1.25
m2, 40 mg b.i.d.; BSA ≥ 1.25 but <1.5 m2; 50 mg b.i.d., and BSA ≥ 1.5 m2: 60 mg b.i.d. One cycle consisted of consecutive administration of
S-1 for 28 days followed by a 2-week rest period, and cycles were repeated up to 4 times. The partial response (PR) rate of the eligible
patients was 22.0% (13/59); (95% confidence interval: 12.3–34.7%). A PR was observed in 22.7% (5/22) of the stage IIIB patients and 21.6%
(8/37) of the stage IV patients. The median response duration was 3.4 months (1.1–13.7 months or longer). Grade 4 neutropenia was
observed in one of the 59 patients (1.7%). The grade 3 or 4 toxicities consisted of decreased haemoglobin level in 1.7% of patients (1/59),
neutropenia in 6.8% (4/59), thrombocytopenia in 1.7% (1/59), anorexia in 10.2% (6/59), diarrhoea in 8.5% (5/59), stomatitis in 1.7% (1/59),
and malaise in 6.8% (4/59), and their incidences were relatively low. There were no irreversible, severe or unexpected toxicities. The median
survival time (MST) of all patients was 10.2 months (95% confidence interval: 7.7–14.5 months), and the one-year survival rate was 41.1%.
The MST of the stage IIIB patients was 7.9 months, and that of the stage IV patients was 11.1 months. The one-year survival rates of the
stage IIIB and IV patients were 30.7% and 47.4%, respectively. S-1 was considered to be an active single agent against NSCLC. Further
study of S-1 with other active agents is warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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Patient eligibility 
Eligible patients were accrued between June 1996 and July 1998.
The patients had histologically or cytologically confirmed stage
IIIB or IV NSCLC and evidence of measurable disease (bone
lesions were excluded from the evaluation). Prior therapy against
NSCLC was an exclusion criterion. Other eligibility criteria
included (1) age ≥ 20 years, but < 75 years, (2) Eastern Cooperative
Oncology Group performance status of 0 to 2, (3) adequate bone
marrow function (white blood cell count ≥ 4 × 109 l–1, but ≤ 12 ×
109 l–1, haemoglobin ≥ 9.0 g dl–1, and platelet count ≥ 100 × 109
l–1), (4) adequate liver function (total bilirubin ≤ 1.5 mg ml–1, AST
and ALT ≤ 100 IU l–1, and alkaline phosphatase ≤ twice the upper
normal limit), (5) adequate renal function (serum creatinine and
blood urea nitrogen ≤ upper normal limit), (6) adequate pulmonary
function (PaO2 ≥ 70 Torr), (7) life expectancy ≥ 3 months, and (8)
written informed consent. 
Chest X-ray, chest computed tomography (CT), brain CT or
magnetic resonance imaging (MRI), bone scintigraphy, and
abdominal CT were used to stage the patients. 
Drug administration 
S-1 was administered orally, twice daily, after meals. 3 doses of S-
1 were selected according to body surface area (BSA) so that they
would be approximately equivalent to 80 mg m–2 day–1: BSA <
1.25 m2, 40 mg b.i.d.; BSA  1.25 m2, but <1.5 m2, 50 mg b.i.d.;
and BSA ≥ 1.5 m2, 60 mg b.i.d. One cycle consisted of consecutive
administration of S-1 for 28 days followed by a 2-week rest
period. The cycle could be repeated up to 4 times if no disease
progression was detected. Patients in whom a complete response
or partial response, as described below, was observed at the time of
completion of the fourth cycle were transferred to the long-term
administration study. Doses of the drug were adjusted according to
haematological (WBC and platelet counts) and non-haematolog-
ical toxicity. The dose was reduced by one level (20 mg day–1) in
patients whose body surface was 1.25 m2 or more, with evidence
of grade 3 or more haematologic toxicity (WBC < 2000 µ l–1 or
platelet counts < 50 000 µ l–1) or grade 2 or more non-haematological
toxicity (except alopecia and anorexia) during any cycle of admin-
istration. If recovery from such toxicities was confirmed at the
reduced dose, administration at the reduced dose was continued. If
a patient with body surface area less than 1.25 m2, experienced the
above toxicities, further treatment with S-1 was not done. If a rest
period of more than 4 weeks was required, the patient was with-
drawn from the study. Antiemetic drugs were not administered
prophylactically. S-1 was provided by Taiho Pharmaceutical Co,
Ltd (Tokyo, Japan). 
Measurements of study end points 
Response was assessed in each cycle by clinical tumour measure-
ments and documentation of the tumour size of measurable
lesions. 
The response to treatment of measurable lesions was evaluated
in accordance with the criteria of the WHO (WHO Handbook for
Reporting Results of Cancer Treatment, 1979). Safety was evalu-
ated according to the Criteria for the Evaluation of the Clinical
Effects of Solid Cancer Chemotherapy published by the Japan
Society for Cancer Chemotherapy (Japan Society for Cancer
Therapy, 1993). These criteria are almost the same as those
published by the WHO, except for diarrhoea (see Table 2). 
A complete response (CR) was defined as disappearance of all
clinical and radiologic evidence of tumour for at least 4 weeks. A
partial response (PR) required a ≥ 50% reduction in the sum of the
products of the perpendicular diameters of all measurable lesions
for at least 4 weeks. Progressive disease (PD) was defined as the
appearance of an unequivocal new lesion or an increase of ≥ 25%
in the sum of the products of the perpendicular diameters of any
measured lesions No change (NC) or stable disease was a change
insufficient for PR or PD for at least 4 weeks after the start of
therapy. In addition, there could be no new lesions or increases in
the size of any nonmeasurable lesions for CR, PR or NC. 
Response duration was defined as the interval between the time
that the criteria for response were first met and the time when
disease progression was objectively documented. All of the judge-
ments, including reported responses, were strictly inspected by
extramural review based on CT scans, radiographs and magnetic
resonance images. Overall survival time was measured as the
interval between the start of S-1 treatment and the date of death or
the date of the last follow-up. The Kaplan–Meier method was used
to estimate overall survival curves (Kaplan and Meier, 1958). 
Compliance was verified by patient interview. The ratio of the
total dose actually administered to the scheduled dose was calcu-
lated for the first cycle. 
The number of patients to be enrolled in this study was calcu-
lated as 60, the number required to refute the assumption that the
95% confidence interval would be 10% under conditions of α =
0.025 (one side) and β = 0.1, assuming an expected response rate
of 25%. 
RESULTS 
62 patients were accured in this study, and 59 were assessable for
response and toxicity. 3 patients were excluded as ineligible for
the reasons described below. The drug was not administered to 1
patient because informed consent was withdrawn. In another
patient, the primary lung cancer was found to be complicated by
gastric cancer at the completion of the first cycle of chemotherapy.
The other patient was judged to be ineligible due to the violation of
one of the eligibility criteria (WBC count >12 × 109 l–1). Tumour
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Table 1 Patient characteristics (n = 59) 
Characteristics No. of Pts. 
Male/female 36/23 
Median age, years (range) 64 (42–74) 
Performance status 
0 18 
1 37 
24  
Median initial dose, mg m–2 (range) 73.4 (64.1–79.5) 
Stage of disease 
IIIB 22 
IV 37 
Histology 
Adenocarcinoma 38 
Squamous cell carcinoma 20 
Lage cell carcinoma 1 
BJOC 01-2031 939-943  1/10/01  11:44 am  Page 940response and toxicities were evaluated in the remaining 59 eligible
patients. The characteristics of these 59 patients are listed in Table 1.
23 patients were female, representing 39% of all patients. Median
age was 64 years, and age ranged from 42–74 years. Most of the
patients had an ECOG performance status (PS) of 0 to 1, and only
4 patients (7%) were PS 2. 22 (37%) patients had stage IIIB
disease, and the other 37 patients had stage IV disease. 38 (64%)
of the 59 patients had adenocarcinoma, and 20 (34%) had squa-
mous cell carcinoma. 
The median follow-up period was 9.2 months (range, 1.6–32.7
months). The date of death was used as the date of the last follow
up for patients who died. 
Antitumour activity 
No CRs were observed in any of the 59 eligible patients, but a PR
was observed in 13 patients, resulting in an overall response rate of
22.0% (95% confidence interval: 12.3–34.7%). The response rate
among all 61 patients given the drug was 21.3% (95% confidence
interval: 11.9–33.7%). Histologically, a PR was observed in 10
(26.3%) of the 38 patients with adenocarcinoma, 2 (10.0%) of the
20 patients with squamous cell carcinoma, and 1 patient with large
cell carcinoma. According to clinical stage, a PR was observed in
22.7% (5/22) of the stage IIIB patients and 21.6% (8/37) of the
stage IV patients. There was little difference in response rate
between the stage IIIB and stage IV patients. The median response
duration was 3.4 months (1.1–13.7 months or longer). As shown in
Figure 1, the median survival time of all patients was 10.2 months
(95% confidence interval: 7.7–14.5 months), and the 1-year
survival rate was 41.1%. The median survival time of the stage IIIB
patients was 7.9 months and that of the stage IV patients was 11.1
months. The 1-year survival rates of the stage IIIB and IV patients,
were 30.7% and 47.4%, respectively. Although the survival of stage
IV patients was longer than that of the stage IIIB patients, there was
no statistically significant difference between them. 
Toxicity 
The major toxicities during the study period are shown in Table 2.
The incidences of the toxicities were evaluated in 59 eligible
patients. Both haematological and non-haematological toxicities
were mild. The toxicities reaching grade 3 or more consisted
of decreased haemoglobin level in 1.7% of patients (1/59),
neutropenia in 6.8% (4/59), and thrombocytopenia in 1.7% (1/59).
The non-haematological grade 3 toxicities were anorexia in 10.2%
(6/59), diarrhoea (grade 3: watery stools lasting more than 4 days)
in 8.5% (5/59) and malaise in 6.8% (4/59). There were no grade
4 non-haematological toxicities. All of these toxicities were
manageable, and the patients recovered when the drug was inter-
rupted. There were no irreversible, severe, or unexpected
toxicities. 
Dose intensity of S-1 
Of the 10 patients who received only one cycle of chemotherapy,
only 1 patient had a PR and 9 patients had a NC. 31 patients
received 2 or more cycles. Of these, 16 patients received 3
cycles and 10 had 4 cycles. The reasons for only one cycle of
treatment are PD in 13 patients, NC in 7 patients, request for
another treatment in 1 patient and toxicities in 7 patients. The
toxicities consisted of grade 3 thrombocytopenia in 1 patient,
grade 2–3 diarrhoea in 3 patients and grade 2–3 anorexia in 3
patients. 
116 cycles were administered to 59 patients. The dose was
reduced in 6 patients because of toxicities. In the first cycle, 59
patients received 90.9% of the planned dose of S-1. The 31
patients in the second cycle received 95.3% of the planned dose of
S-1, the 16 patients in the third cycle received 90.0%, and the 10
patients in the fourth cycle received 100%. 
DISCUSSION 
Recent chemotherapeutic agents used as single-agent therapy to
treat chemotherapy-naïve NSCLC include paclitaxel, docetaxel,
vinorelbine, gemcitabine, and irinotecan, and the response rates
have ranged from approximately 15–30% (Devita, 1997). In this
study of S-1, responses were observed in 13 patients, with a
response rate of 22.0% (13/59) and 95% CI of 12.3–34.7%. This
Phase II study of S-1 for NSCLC 941
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Table 2 Toxicity (n = 59) 
Grade Grade 3–4 
1 2 3 4 (%) 
Haematological 
Leukopenia 12 7 0 0 
Neutropenia 11 5 3 1 6.8 
Haemoglobin 8 10 1 0 1.7 
Thrombocytopenia 5 1 1 0 1.7 
Non-Haematological 
GOT (AST) 6 2 0 0 
GPT (ALT) 3 3 0 0 
Bilirubin 3 1 0 0 
Anorexia 13 7 6 0 10.2 
Nausea & vomiting 17 6 0 0 
Diarrhoea*
a 7 3 5 0 8.5 
Stomatitis 10 3 1 0 1.7 
Eruption 5 3 0 0 
Pigmentation 10 3 0 0 
Malaise 5 5 4 0 6.8 
*
aGrade of diarrhoea (duration of days): Grade 1 muddy stool (2–3); Grade 2
watery stool (3–4); Grade 3 watery stool (≥ 5); Grade 4 hemorrhagic,
dehydration. 
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with NSCLC. Various 5-FU derivatives, such as tegafur (Ansfield et
al, 1983), UFT (Keicho et al, 1986), and 5’-deoxy-5-fluorouridine
(5′ DFUR) (Hara, 1984; Niitani et al, 1985) have been developed to
potentiate anticancer activity by preventing 5-FU degradation or
sustain the concentration of 5-FU in the blood, but none of them
have yielded a good response rate of more than 15% (Ota et al,
1988). However, rationally engineered and metabolically activated
DPD inhibiting fluoropyrimidines (DIF) have recently been devel-
oped, as exemplified by S-1 and BOF-A2. BOF-A2, which has a
18% response rate (Nakai et al, 1994), is reported to be active
against NSCLC. The mechanism of action is the same as that of 
S-1. There are several possible explanations for the enhanced
activity of DIF such as S-1 or BOF-A2. In an in vitro study, S-1
had a higher therapeutic effect on human colon carcinoma
implanted into nude rats than UFT did (Shirasaka et al, 1996). In
vitro, CDHP has been shown to exert DPD inhibitory activity 180-
fold higher than that of uracil, which has been confirmed to be a
DPD inhibitor in the form of UFT (Tatsumi et al, 1987). Another
point is that orally administered S-1 mimics prolonged continuous
5-FU infusion. A pharmacokinetic study of S-1 has been reported
by Hirata et al (1999). They reported that there were no fluctua-
tions in pharmacokinetics and no drug accumulation during a 28-
day consecutive regimen of S-1, and that pharmacokinetic
parameters of oral S-1 are almost the same to those of continuous
i.v. infusion of 5-FU. Capecitabine is also capable of mimicking
the mechanism of action of continuous infusion of 5-FU. This
drug, not belonging to the DIF, is a prodrug that is metabolized to
5-FU upon absorption from the gastrointestinal tract. This drug is
active against colorectal cancer and breast cancer (Blum et al,
1999; Cutsem et al, 2000). However, the activity of this drug
against NSCLC has not been reported. 
As regards haematological toxicity, grade 3 or more neutropenia
was observed in only 4 patients (6.8%). Grade 3 anaemia and
thrombocytopenia were observed only in 1 patient each (1.7%).
The major non-haematological toxicities were anorexia (grade 3,
10.2%), diarrhoea (grade 3, 8.5%), and fatigue (grade 3, 6.8%),
and they were mild and tolerable. The frequency of grade 3 or
more adverse reactions was 2–4%, and there were no grade 4
adverse reactions. All of these toxicities are consistent with 
5-FU-related toxicity. Oxo should protect against diarrhoea by
selectively inhibiting 5-FU phosphorylation via orotate phosphori-
bosyltransferase in normal gastrointestinal tissue while mini-
mizing its inhibition in tumour tissues (Shirasaka et al, 1993). The
incidence of major toxicities associated with administration of
UFT in phase II trials in various cancers have been 4% for
leukopenia and 11% for diarrhoea (n = 551) (Ota et al, 1988). The
incidence of toxicities in our S-1 study was lower than observed
for UFT. 
116 cycles were administered to 59 patients, and the dose was
reduced because of toxicities in only 6 patients. The high relative
dose intensity of 90.0–100% during each cycle indicates that S-1 is
easy to administer. This treatment is associated with fewer toxici-
ties and outpatient treatment is feasible. 
In this study, the median survival time of the stage IIIB patients
was 7.9 months and that of the stage IV patients was 11.1 months.
The survival time of stage IV patients seems longer than that of the
stage IIIB patients, but the difference was not statistically significant.
This may be due to small number of stage IIIB patients (22 patients). 
At the time of this writing, S-1 has been approved in Japan for use
in gastric cancer alone. Because of the limited indication for S-1,
there have not been any combination chemotherapy trials of S-1 in
NSCLC. Thus far, 3 phase II combination studies of another previ-
ously developed fluoropyrimidine derivative, UFT, plus cisplatin
have been conducted in advanced NSCLC in Japan. In one trial by
Nakai and Colleagues (Nakai et al, 1999), UFT was administered
at 400 mg m–2 on days 1 through 21 with cisplatin at 20 mg m–2 on
days 8 through 12. The response rate was 38.3% among 47
patients, and the MST was 12.8 months. In another study, by
Yoshimori and Coworbers (Yoshimori et al, 1998), UFT was used
on days 1 through 14 with cisplatin at 80 mg m–2 on day 8. The
response rate was 29% among 108 patients with a MST of 9.4
months. The other trial, by Ichinose et al, (1995), UFT 400 mg m–2
on days 1 through 21 with cisplatin 80 mg m–2 on day 8 was used.
The response rate was 35% among 31 patients with median
survival times of 11 months in the stage IIIB patients and 8 months
in the stage IV patients. All trials reported an extremely low inci-
dence of side effects, including neutropenia. The activity of UFT
plus cisplatin is comparable to that of other cisplatin-based regi-
mens, and the combination is well tolerated. These findings
suggest that replacement of UFT by S-1 will further improve the
response rate and survival will also improve. A study of S-1 plus
cisplatin is planned. 
In conclusion, our study indicates that S-1 is active in the treat-
ment of NSCLC and provides a significant response rate with
tolerable toxicity. The oral formulation and low incidence of
adverse reactions permit treatment on an outpatient basis. S-1 is
therefore considered to be a very convenient drug for patients.
Further assessment in combination with other active agents is
warranted. 
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APPENDIX 
Additional participating institutions and principal investigators:
Hiroshi Isobe, Department of Respiratory Disease, National
Sapporo Hospital, Sapporo; Toshihiro Nukiwa, Respiratory
Oncology and Melecular Medicine, Institute of Development,
Aging and Cancer, Tohoku University, Miyagi; Akira Yokoyama,
Department of Internal Medicine, Niigata Cancer Center Hospital,
Niigata; Hiroshi Sakai, Department of Respiratory Disease,
Saitama Cancer Center, Saitama; Mitunori Hino, Department of
Internal Medicine, Chiba-Hokusou Hospital, Nippon Medical
School, Chiba; Takahiko Sugiura, Department of Pulmonary
Disease, Aichi Cancer Center, Aichi; Hiromi Wada, Institute for
Frontier Medical Sciences, Kyoto University, Kyoto; Syunichi
Negoro, Department of Pulmonary Medicine, Osaka City General
Hospital, Osaka; Minoru Takada, Department of Respiratory
Disease, Izumisano Municipal Hospital, Osaka; Soichiro Yokota,
Department of Internal Medicine, Toneyama National Hospital,
Osaka; Yoshiki Takada, Department of Radiology, Hyogo Medical
Center for Adult Diseases, Hyogo; Hiroshi Ueoka, Second
Department of Internal Medicine, Okayama University School of
Medicine, Okayama; Michio Yamakido, Second Department of
Internal Medicine, Hiroshima University School of Medicine;
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The Chest, Research Institute for Diseases of The Chest, Faculty
of Medicine, Kyushu University, Fukuoka; Yukito Ichinose,
Department of Chest Surgery, National Kyushu Cancer Center,
Fukuoka; Hidehiko Yamamoto, Department of Pulmonary
Disease, Aso Cement Iizuka Hospital, Fukuoka. 
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